Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $82.